Key points are not available for this paper at this time.
Endometrial cancer is the sixth most prevalent cancer among women and the thirteenth cause of mortality in women worldwide. It is the eighth most prevalent cancer in women in Egypt and the fifteenth cause of mortality in women in Egypt. Endometrioid endometrial carcinoma is the most common type (70%) of endometrial cancer. Most patients diagnosed at an early stage had good prognoses. However, some individuals with low-grade, low-stage cancers experience recurrence. Prediction of recurrence in those patients is crucial to improve prognosis. CTNNB1 gene mutation is suggested to be associated with endometrial cancer recurrence. CTNNB1 encodes beta-catenin protein.β-catenin is an important mediator in the Wnt/β-catenin signaling pathway. Exon 3 mutations in the CTNNB1 gene activate the canonical Wnt/β-catenin signaling pathway, leading to development of cancer.Aim:The aim of the present study was to study CTNNB1 exon 3 somatic mutations in early stage endometrial cancer in a cohort of Egyptian patients. Patient and Methods:SUBJECTS: This study was conducted on 40 patients with early stage (stage I recurrent Group (20 patients with recurrent endometrial cancer who developed metastasis or insitu recurrence) and non recurrent group (20 patients with early stage endometrioid endometrial carcinoma with no recurrence after remission). Formalin fixed paraffin embedded (FFPE) samples were obtained from the Pathology departments at Alexandria University.
Zakaria et al. (Mon,) studied this question.